ADVERTISEMENT

Coronavirus India Latest Updates: Active Cases Decline To 1.42 Lakh, Cadila To Supply One Crore Vaccines

Follow the latest updates on the coronavirus pandemic and vaccination numbers in India here.

<div class="paragraphs"><p>Police conduct random checks of Covid-19 safety protocols. (Photographer: Anindito Mukherjee/Bloomberg)</p></div>
Police conduct random checks of Covid-19 safety protocols. (Photographer: Anindito Mukherjee/Bloomberg)

India's active caseload continued to decline as daily recoveries exceeded fresh cases for the third day in a row.

India added 11,451 fresh cases in the last 24 hours, with the tally rising above to 3.43 crore in the world’s second-most populous country, according to the Health Ministry’s update as of 8 a.m. on Nov. 8. That compares with 13,204 recoveries made in the same period.

Active cases fell further to 1.42 lakh, and now make up 0.42% of India's total tally, the lowest since March 2020.

Key figures:

  • Total confirmed cases: 3,43,66,987

  • Total number of active cases: 1,42,826

  • Total patients cured/discharged/migrated: 3,37,63,104

  • Total deaths: 4,61,057

  • Number of fresh cases in last 24 hours: 11,451

  • One-day recoveries: 13,204

  • One-day deaths: 266

  • Vaccines administered in the last 24 hours: 23,84,096

  • Total vaccines given: 1,08,47,23,042

Opinion
Flights to U.S. Reopen; German Cases Spike: Virus Update

Cadila To Supply One Crore Vaccine Doses To Centre

Cadila Healthcare Ltd. has received an order to supply one crore doses of its three-dose intradermal plasmid DNA vaccine to the Government of India. This makes it the fourth vaccine to be approved for use in India after Serum Institute’s Covishield, Bharat Biotech’s Covaxin and the Russian Covid-19 vaccine-Sputnik.

ZyCov-D, the world’s first plasmid DNA vaccine which comes with a needle-free applicator has been priced at Rs 265 per dose while the applicator would be offered at Rs 93 per dose. This price is excluding GST. The vaccine has a primary established efficacy of 66.66% for the symptomatic RT-PCR positive cases and the jab has been found safe for children in the age group of 12-18 years.